Retinal Biologics Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Retinal Biologics Market," The retinal biologics market was valued at $14.9 billion in 2022, and is estimated to reach $24.7 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032.

One of the most well-known biologics used in the treatment of retinal conditions is Ranibizumab (brand name Lucentis), which is used for age-related macular degeneration and macular edema. Another commonly used biologic is aflibercept (brand name Eylea), which targets AMD age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Bevacizumab (brand name Avastin), although primarily approved for cancer treatment, is sometimes used off-label in ophthalmology for similar indications.

The retina biologics market has experienced significant growth owing to rise in prevalence of retinal diseases, rise in geriatric population suffering from retinal disorders diseases, and advancements in biotechnology and ophthalmic research. For instance, according to the (NCBI) in 2020, approximately 196 million people worldwide to affected by AMD, with a global prevalence of 8.69%. In addition, increase in awareness among patients and healthcare professionals about the efficacy and benefits of biologic therapies drive the market growth.

Furthermore, ongoing research and development activities in the field of retinal biologics contribute to market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available retinal biologics. For instance, Atsena Therapeutics Inc. conducting a clinical trial to evaluate the safety and tolerability of ATSN-201 in male subjects 6 to 64 years old with RS1-associated X-linked retinoschisis (XLRS).

Moreover, advances in biotechnology, such as genetic engineering, recombinant DNA technology, and targeted drug delivery systems, have revolutionized the field of retinal biologics that support the market growth. These advancements have enabled the development of highly targeted and efficacious therapies that specifically address the underlying mechanisms of retinal diseases, improving treatment outcomes and driving the market growth. However, high cost of retinal drugs may limit the adoption of retinal biologic drugs and restrain the market growth.

The retinal biologics market is segmented into drug class, indication, distribution channel, and region. On the basis of drug class, the market is bifurcated into VEGF-A antagonist and others. The VEGF-A antagonist segment is further categorized into Aflibercept, Ranibizumab, and others. On the basis of indication, the market is categorized into macular degeneration, diabetic retinopathy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the retinal biologics market are AbbVie Inc., Amgen Inc., Bayer AG, Biocon, Biogen, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. Key players have adopted product launch, product approval, and collaboration as key developmental strategies to improve the product portfolio of the retinal biologics market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the retinal biologics market analysis from 2022 to 2032 to identify the prevailing retinal biologics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the retinal biologics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global retinal biologics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

By Drug Class

VEGF-A Antagonist
- Type
- Aflibercept
- Ranibizumab
- Others
Others

By Indication

Macular Degeneration
Diabetic Retinopathy
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East And Africa

Key Market Players:

AbbVie Inc.
Amgen Inc.
Bayer AG
Biocon
Biogen
Coherus BioSciences, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Outlook Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc.

Product Code: A10946

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in strategic Initiatives by several organizations
  - 3.4.1.2. Increase in prevalence of retinal diseases
  - 3.4.1.3. Increase in geriatric population

3.4.2. Restraints
- 3.4.2.1. High cost of biologic drugs

3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.4.3.2. Rise in R&D activities

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: RETINAL BIOLOGICS MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. VEGF-A Antagonist
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. VEGF-A Antagonist Retinal Biologics Market by Type
4.3. Others
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: RETINAL BIOLOGICS MARKET, BY INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Macular Degeneration
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Diabetic Retinopathy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: RETINAL BIOLOGICS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug Class
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug Class
  - 7.2.5.1.3. Market size and forecast, by Indication
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug Class
  - 7.2.5.2.3. Market size and forecast, by Indication
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug Class
  - 7.2.5.3.3. Market size and forecast, by Indication
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug Class
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug Class
  - 7.3.5.1.3. Market size and forecast, by Indication
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug Class
  - 7.3.5.2.3. Market size and forecast, by Indication
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug Class
  - 7.3.5.3.3. Market size and forecast, by Indication
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug Class
  - 7.3.5.4.3. Market size and forecast, by Indication
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug Class
  - 7.3.5.5.3. Market size and forecast, by Indication
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug Class
  - 7.3.5.6.3. Market size and forecast, by Indication
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug Class
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug Class
  - 7.4.5.1.3. Market size and forecast, by Indication
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug Class
  - 7.4.5.2.3. Market size and forecast, by Indication
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug Class
  - 7.4.5.3.3. Market size and forecast, by Indication
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug Class
  - 7.4.5.4.3. Market size and forecast, by Indication
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug Class
  - 7.4.5.5.3. Market size and forecast, by Indication
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug Class
  - 7.4.5.6.3. Market size and forecast, by Indication
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug Class
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Latin America
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug Class
  - 7.5.5.1.3. Market size and forecast, by Indication
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Middle East And Africa
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug Class
  - 7.5.5.2.3. Market size and forecast, by Indication
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. F. Hoffmann-La Roche Ltd.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Regeneron Pharmaceuticals, Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Biogen
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Coherus BioSciences, Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Bayer AG
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. AbbVie Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Biocon
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Outlook Therapeutics, Inc.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
9.10. Amgen Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance